BACKGROUND: This study examines whether preoperative ultrasound-assessed tumour diameter and diagnostic core biopsy-determined grade can be used to select those most likely to benefit from SLNB (i.e. those that are "node negative") before their definitive operation. METHODS: Breast ultrasound (US) and a simultaneous core biopsy was performed in all patients at their initial presentation, and their estimates of tumor size and grade compared with the final pathological specimen (FPS). RESULTS: Of the T1 group 47% had lymphatic metastases as did 49% of those with grade I or II cancers. By combining these measures, however, subgroups of patients with lower rates of nodal metastases were identified (32% of patients with T1, non-grade III disease had lymphatic disease while only 15% of those with T < 1.5 cm, non-grade III cancers had such metastases). CONCLUSION: Combination of the US and ultrasound guided core biopsy (UGCB) may however identify subgroups unlikely to have axillary disease that are therefore suitable for SLNB.
BACKGROUND: This study examines whether preoperative ultrasound-assessed tumour diameter and diagnostic core biopsy-determined grade can be used to select those most likely to benefit from SLNB (i.e. those that are "node negative") before their definitive operation. METHODS: Breast ultrasound (US) and a simultaneous core biopsy was performed in all patients at their initial presentation, and their estimates of tumor size and grade compared with the final pathological specimen (FPS). RESULTS: Of the T1 group 47% had lymphatic metastases as did 49% of those with grade I or II cancers. By combining these measures, however, subgroups of patients with lower rates of nodal metastases were identified (32% of patients with T1, non-grade III disease had lymphatic disease while only 15% of those with T < 1.5 cm, non-grade III cancers had such metastases). CONCLUSION: Combination of the US and ultrasound guided core biopsy (UGCB) may however identify subgroups unlikely to have axillary disease that are therefore suitable for SLNB.
Authors: U Veronesi; G Paganelli; V Galimberti; G Viale; S Zurrida; M Bedoni; A Costa; C de Cicco; J G Geraghty; A Luini; V Sacchini; P Veronesi Journal: Lancet Date: 1997-06-28 Impact factor: 79.321
Authors: James W Jakub; Mark D Ebert; Nils M Diaz; Alan Cantor; Douglas S Reintgen; Elisabeth L Dupont; Alan R Shons; Charles E Cox Journal: Ann Surg Date: 2003-06 Impact factor: 12.969
Authors: Samuel W Beenken; Marshall M Urist; Yuting Zhang; Renee Desmond; Helen Krontiras; Heriberto Medina; Kirby I Bland Journal: Ann Surg Date: 2003-05 Impact factor: 12.969
Authors: Rohanna Ali; Ann M Hanly; Peter Naughton; Constantino F Castineira; Rob Landers; Ronan A Cahill; R Gordon Watson Journal: World J Surg Oncol Date: 2008-06-26 Impact factor: 2.754